Genmab Sustainability Profile
Genmab A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to developing differentiated antibody therapeutics. Founded in 1999, Genmab has made significant strides in the biopharmaceutical industry, focusing primarily on oncology and immunology. With a robust pipeline of proprietary and partnered products, Genmab's core offerings include monoclonal antibodies that target various cancers, distinguished by their unique mechanisms of action. The company has achieved notable milestones, including the successful development of its flagship product, Darzalex, which has transformed treatment paradigms for multiple myeloma. Positioned as a key player in the global biotechnology landscape, Genmab continues to expand its influence through strategic collaborations and a commitment to scientific excellence, solidifying its reputation as a pioneer in the field.
DitchCarbon Score
How does Genmab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genmab's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genmab's reported carbon emissions
In 2024, Genmab reported total carbon emissions of approximately 189.7 million kg CO2e. This figure includes Scope 1 emissions of about 534,000 kg CO2e, Scope 2 emissions of approximately 1,163,000 kg CO2e (market-based), and significant Scope 3 emissions totalling around 188 million kg CO2e. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (approximately 164.4 million kg CO2e) and business travel (about 10.6 million kg CO2e). In 2023, Genmab's total emissions were approximately 151.5 million kg CO2e, with Scope 1 emissions at about 317,000 kg CO2e, Scope 2 emissions of approximately 238,000 kg CO2e (market-based), and Scope 3 emissions reaching around 150.9 million kg CO2e. The 2022 data shows total emissions of about 147.7 million kg CO2e, with Scope 1 at approximately 283,000 kg CO2e, Scope 2 at about 111,000 kg CO2e, and Scope 3 at around 147.3 million kg CO2e. Despite the detailed emissions reporting, Genmab has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from any parent organization, ensuring that the reported figures are solely reflective of Genmab A/S's operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 341,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 298,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Genmab's Industry?
How Carbon Intensive is Genmab's Location?
Genmab's Scope 3 Categories Breakdown
Genmab's Scope 3 emissions, which increased by 25% last year and increased by approximately 28% since 2022, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 87% of Scope 3 emissions.
Top Scope 3 Categories
Genmab's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Genmab has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.